<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895596</url>
  </required_header>
  <id_info>
    <org_study_id>BVCL004</org_study_id>
    <nct_id>NCT00895596</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B</brief_title>
  <official_title>A PhaseII, Open-Label, Multinational, Multi-Centre, Sequential Group, Dose-Escalation Study to Assess the Safety and Antiviral Activity of LB80380 for 12 Weeks in Patients With Lamivudine-Refractory Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and the antiviral activity of ascending&#xD;
      multiple oral doses of LB80380 for 12 weeks in adults with lamivudine-refractory chronic&#xD;
      hepatitis B infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LB80380, an oral prodrug, is a promising candidate nucleoside analogue with antiviral&#xD;
      activity against wild-type HBV. LB80380 is undergoing clinical development by LG Life&#xD;
      Sciences for use in the treatment of chronic HBV infection and for treatment of&#xD;
      lamivudine-resistant disease.&#xD;
&#xD;
      In this study, the treatment period was divided into two parts: a 4-week treatment period&#xD;
      with dose escalation assessment (Part 1), followed by an 8-week extension period (Part 2).&#xD;
&#xD;
      During Part 1, patients received LB80380 and LVD 100 mg once daily for 4 weeks. Each patient&#xD;
      was then given only LB80380 for an additional 8 weeks (Part 2) unless dose-limiting toxicity&#xD;
      (DLT) was observed during Part 1. At each dose level, all patients were to complete at least&#xD;
      Part 1 of the treatment period before enrolment into the next Dose Group could commence. Dose&#xD;
      escalation to the next group was not to be initiated if more than two patients experienced&#xD;
      DLT during Part 1 in the previous Dose Group. Additionally, patients enrolled in LB80380&#xD;
      150mg and 240mg groups who agreed to participate in the pharmacokinetic (PK) analyses visited&#xD;
      the study site the day before Week 12 for blood sampling. Follow-up period was 24 weeks, and&#xD;
      patients were treated with adefovir dipivoxil during the follow-up period. During the study,&#xD;
      patients were evaluated for changes from baseline in serum HBV DNA. Safety was evaluated on&#xD;
      the basis of occurrence of AEs and changes from baseline in clinical laboratory parameters,&#xD;
      physical examination findings, and vital signs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean serum HBV DNA level (log10) reduction from the baseline at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBeAg seroconversion at 12 weeks Proportion of patients with HBsAg seroconversion at 12 weeks Proportion of patients with ALT normalization at 12 weeks Safety assessment during the whole study period</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>LB80380 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB80380 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB80380 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB80380 60mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB80380 90mg,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB80380 90mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB80380 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB80380 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB80380 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB80380 240mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB80380</intervention_name>
    <description>Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg</description>
    <arm_group_label>LB80380 150mg</arm_group_label>
    <arm_group_label>LB80380 240mg</arm_group_label>
    <arm_group_label>LB80380 30mg</arm_group_label>
    <arm_group_label>LB80380 60mg</arm_group_label>
    <arm_group_label>LB80380 90mg,</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Compensated chronic hepatitis B patient&#xD;
&#xD;
          -  Presence of serum HBsAg for more than 6 months.&#xD;
&#xD;
          -  Presence of HBeAg for more than 1 month with compensated liver disease&#xD;
&#xD;
          -  Confirmation of YMDD mutants (M552V, M552I and its related double mutant at L528M) by&#xD;
             genotyping of the YMDD motif using line probe assay (INNO-LiPA HBV DR assay)&#xD;
&#xD;
          -  Screening HBV DNA value higher than or equal to 1,000,000 copies/mL (measured by the&#xD;
             COBAS Amplicor HBV Monitorâ„¢ assay)&#xD;
&#xD;
          -  Screening ALT value between 1.5 and 10 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-infection with hepatitis C or D virus (HCV or HDV) or HIV&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Previous treatment with nucleoside analogue or any other treatment for HBV except for&#xD;
             lamivudine within 6 months prior to study entry&#xD;
&#xD;
          -  Treatment with immunomodulatory agent or corticosteroids within 6 months prior to&#xD;
             study entry.&#xD;
&#xD;
          -  De-compensated liver disease&#xD;
&#xD;
          -  Screening alpha-fetoprotein (AFP) value &gt; 20 ng/mL, and a follow-up ultrasonography&#xD;
             performed prior to baseline shows findings indicative of HCC.&#xD;
&#xD;
          -  Presence of anti-HBs at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Lung Lai, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital of Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <last_update_submitted>May 7, 2009</last_update_submitted>
  <last_update_submitted_qc>May 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>LG Life Sciences, Ltd.</name_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Lamivudine resistant</keyword>
  <keyword>YMDD mutant type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

